rivaroxaban
Investigation questions Xarelto trial data accuracy
February 4, 2016Medical Communications BMJ, Bayer, INR, Johnson & Johnson, New England Journal of Medicine, Rocket-AF, Xarelto, blood clotting, rivaroxaban
The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from …
Bayer backs safety of Xarelto after real-world data study
September 2, 2015Research and Development Bayer, ESC, European Society of Cardiology, Xarelto, anticoagulants, atrial fibrillation, real-word evidence, rivaroxaban
Around 96 in every 100 people treated with Bayer’s anticoagulant Xarelto do not experience any major bleeding, related side effects …
Bayer promotes Xarelto benefits
June 15, 2015Sales and Marketing Bayer, Eliquis, Xarelto, blood, law suits, rivaroxaban
Bayer HealthCare is releasing new evidence to suggest that the risk of taking its best-selling blood thinner Xarelto is outweighed …
Bayer launches major new stroke trial
January 27, 2015Research and Development, Sales and Marketing Bayer, Canadian Stroke Prevention Intervention Network, Population Health Research Institute, Xarelto, rivaroxaban, stroke
Bayer is enrolling more than 7,000 people in a trial to test whether its blood-thinning drug Xarelto can successfully prevent …
NICE recommends Bayer heart attack drug
January 26, 2015Sales and Marketing ACS, Bayer, J&J, JJ, NICE, Xarelto, q4, rivaroxaban
NICE has recommended Xarelto in final draft guidance as an option for preventing blood clots in people who have had …
Bayer ‘disappointed’ with FDA
February 18, 2014Sales and Marketing ACS, Bayer, Xarelto, blood, rivaroxaban
Bayer HealthCare has expressed its dismay after the Food and Drug Administration once again rejected further indications for the company’s …
Bayer submits new Xarelto indications for European approval
January 6, 2011Sales and Marketing Bayer, DVT, Xarelto, atrial fibrillation, deep vein thrombosis, pulmonary embolism, rivaroxaban, stroke prevention
Bayer is seeking European regulatory approval for a batch of new indications for its oral anticoagulant Xarelto. The company is …
